Lupin Limited — Updates, 11-08-2025: Press Release

Lupin has launched Glucagon for Injection USP, 1mg/vial, as an emergency kit in the United States. This key business development is bioequivalent to Eli Lilly's product, addressing severe hypoglycemia in diabetic patients and serving as a diagnostic aid. The move positions Lupin to capture a share of this market, which saw estimated annual U.S. sales of USD 122 million. This strategic launch enhances Lupin's product portfolio and U.S. market footprint, signaling a positive step for future revenue streams.